KIRKLAND, QC, Sept. 19, 2024 /CNW/ - Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in older adults in Canada for 2024-2025. ABRYSVO™ is approved by Health Canada for the prevention of lower respiratory tract disease caused by RSV in adults 60 years of age and older.i ABRYSVO™ is also the only RSV vaccine authorized for the prevention of RSV in infants via immunization of pregnant individuals.ii RSV is a contagious respiratory virus that disproportionately impacts older adults, especially those who have underlying medical conditions, weakened immune systems or those living in long-term care.iii
Read more at newswire.cahello world
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.
